Details for Patent: 10,709,673

Which drugs does patent 10,709,673 protect, and when does it expire?

Patent 10,709,673 protects EPIDIOLEX and is included in one NDA.

This patent has thirty-two patent family members in nineteen countries.

Summary for Patent: 10,709,673

Title:	Use of cannabinoids in the treatment of epilepsy
Abstract:	The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Inventor(s):	Guy; Geoffrey (London, GB)
Assignee:	GW Research Limited (Cambridge, GB)
Application Number:	16/570,220
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 10,709,673

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 10,709,673

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	1418171.3	Oct 14, 2014

International Family Members for US Patent 10,709,673

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015332212
Australia	2021204353
Australia	2023258400